Health / Business
Add as a preferred source on GoogleValidation results were pending at the Oct. 23 earnings call. The company retained its FY27 goal of 6 million to 7 million devices.
Dr. Reddy’s Laboratories Limited is aiming for a November 2026 return of generic semaglutide, while validation results remained outstanding at its Oct. 23 earnings call.
CEO Erez Israeli expressed confidence in the validation outcome during the call, though the results had not been announced by then.
The company also retained its FY27 target of 6 million to 7 million devices.
The tally includes 20 procedures involving children and 24 involving adults, but does not show how many patients might otherwise have sought care abroad.
PUB says it conducts close to 500,000 water-quality tests annually and uses online sensors at treatment stages and service reservoirs.
Premium Times reported that Commissioner Akin Abayomi cited regular travel between Lagos and Abuja as a reason for the state’s heightened attention.
